Danaher Corporation DHR
i
Market dataready · fetched 2026-11-07T07:18:19.211Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:00:00.003810073Z
FundamentalsSEC EDGAR · ready · as of 2026-09-25 · fetched 2026-11-07T07:18:18.343998+00:00
Danaher Corporation options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 220.87 | 40.3% | 4.7% | |||
| 25Δ | 237.68 | 34.8% | 3.9% | 222.36 | 42.8% | 4.3% |
| 30Δ | 236.12 | 34.8% | 3.4% | 224.11 | 43.2% | 3.8% |
| 35Δ | 234.68 | 35.3% | 3.0% | 225.91 | 42.4% | 3.2% |
| 40Δ | 233.40 | 36.8% | 2.7% | 227.68 | 40.5% | 2.6% |
| 45Δ | 232.09 | 37.1% | 2.4% | 229.20 | 39.3% | 2.2% |
| 50Δ | 230.69 | 34.7% | 1.9% | 230.68 | 38.6% | 1.9% |
| 55Δ | 229.28 | 34.7% | 1.6% | 232.13 | 38.6% | 1.6% |
| 60Δ | 227.86 | 37.0% | 1.5% | 233.59 | 38.4% | 1.3% |
| 65Δ | 226.59 | 36.2% | 1.2% | 235.06 | 38.1% | 1.1% |
| 70Δ | 225.37 | 34.3% | 0.9% | 236.68 | 38.1% | 0.8% |
| 75Δ | 223.76 | 34.6% | 0.7% | 238.56 | 38.6% | 0.7% |
| 80Δ | 222.05 | 35.0% | 0.6% | 240.74 | 39.3% | 0.5% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 220.87
- IV
- 40.3%
- B/E move
- 4.7%
25Δ
- Pseudo strike
- 237.68
- IV
- 34.8%
- B/E move
- 3.9%
- Pseudo strike
- 222.36
- IV
- 42.8%
- B/E move
- 4.3%
30Δ
- Pseudo strike
- 236.12
- IV
- 34.8%
- B/E move
- 3.4%
- Pseudo strike
- 224.11
- IV
- 43.2%
- B/E move
- 3.8%
35Δ
- Pseudo strike
- 234.68
- IV
- 35.3%
- B/E move
- 3.0%
- Pseudo strike
- 225.91
- IV
- 42.4%
- B/E move
- 3.2%
40Δ
- Pseudo strike
- 233.40
- IV
- 36.8%
- B/E move
- 2.7%
- Pseudo strike
- 227.68
- IV
- 40.5%
- B/E move
- 2.6%
45Δ
- Pseudo strike
- 232.09
- IV
- 37.1%
- B/E move
- 2.4%
- Pseudo strike
- 229.20
- IV
- 39.3%
- B/E move
- 2.2%
50Δ
- Pseudo strike
- 230.69
- IV
- 34.7%
- B/E move
- 1.9%
- Pseudo strike
- 230.68
- IV
- 38.6%
- B/E move
- 1.9%
55Δ
- Pseudo strike
- 229.28
- IV
- 34.7%
- B/E move
- 1.6%
- Pseudo strike
- 232.13
- IV
- 38.6%
- B/E move
- 1.6%
60Δ
- Pseudo strike
- 227.86
- IV
- 37.0%
- B/E move
- 1.5%
- Pseudo strike
- 233.59
- IV
- 38.4%
- B/E move
- 1.3%
65Δ
- Pseudo strike
- 226.59
- IV
- 36.2%
- B/E move
- 1.2%
- Pseudo strike
- 235.06
- IV
- 38.1%
- B/E move
- 1.1%
70Δ
- Pseudo strike
- 225.37
- IV
- 34.3%
- B/E move
- 0.9%
- Pseudo strike
- 236.68
- IV
- 38.1%
- B/E move
- 0.8%
75Δ
- Pseudo strike
- 223.76
- IV
- 34.6%
- B/E move
- 0.7%
- Pseudo strike
- 238.56
- IV
- 38.6%
- B/E move
- 0.7%
80Δ
- Pseudo strike
- 222.05
- IV
- 35.0%
- B/E move
- 0.6%
- Pseudo strike
- 240.74
- IV
- 39.3%
- B/E move
- 0.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 29.40% | |
| 28.27% | |
| 29.39% | |
| 30.95% | |
| 26.86% | |
| 28.44% | |
| 32.32% | |
| 33.19% | |
| 39.53% | |
| 30.27% | |
| 33.14% | |
| 31.85% | |
| 33.13% | |
| 34.84% | |
| 28.20% | |
| 31.57% | |
| 31.97% | |
| 31.52% | |
| 31.07% | |
| 27.94% | |
| 32.26% | |
| 30.22% | |
| 32.04% | |
| 28.49% | |
| 32.30% | |
| 33.44% | |
| 32.37% | |
| 34.05% | |
| 30.03% | |
| 32.50% | |
| 32.33% | |
| 33.13% | |
| 34.20% | |
| 32.41% | |
| 34.89% | |
| 35.65% | |
| 35.85% | |
| 38.40% | |
| 36.04% | |
| 39.83% | |
| 39.65% | |
| 43.06% | |
| 42.14% | |
| 42.12% | |
| 44.45% | |
| 47.07% | |
| 52.87% | |
| 47.58% | |
| 49.54% | |
| 55.27% | |
| 64.51% | |
| 37.65% | |
| 35.09% | |
| 32.42% | |
| 32.12% | |
| 30.59% | |
| 32.97% | |
| 32.30% | |
| 31.27% |
Diagnostics & Research
FLGT
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in…
More →GH
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood…
More →GRAL
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection…
More →ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and…
More →IDXX
Description unavailable
More →ILMN
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and…
More →